Turkish scientists develop groundbreaking method to prevent fluid buildup in lungs

A team of six scientists from two universities in Malatya has developed a revolutionary method to treat lung membrane inflammations and prevent recurrent fluid buildup. The groundbreaking approach utilizes a modified sterile talc application and has entered the animal testing phase.

Tackling persistent medical challenges

Pleural effusion, the accumulation of excess fluid in the space between the lung membranes, often leads to respiratory complications. In severe cases, the condition can result in lung collapse, known as pneumothorax, requiring immediate intervention. While traditional methods drain the excess fluid, they do not prevent recurrence.

To address this issue, researchers from Inonu University and Malatya Turgut Ozal University have patented a novel technique aimed at permanently resolving the problem. The approach involves using chemically modified talc powder to seal the lung membranes, preventing future fluid accumulation while ensuring the lungs continue to function smoothly.

New approach: Modified sterile talc with antibacterial properties

Professor Hakan Parlakpinar, Head of the Department of Medical Pharmacology at Inonu University, emphasized the significance of their innovation:

“In cases of chronic pneumothorax, where the lungs collapse repeatedly, the pleural membrane must be sealed to prevent further complications. Our method employs a modified sterile talc that not only creates a chemical adhesion but also retains a lubricating effect, allowing the lungs to operate efficiently.”

Unlike conventional pleurodesis treatments, which solely rely on talc to promote adhesion, this new approach integrates an antibacterial agent within the talc particles. “We combined two separate treatments into one, enhancing their effects while maintaining safety,” Parlakpinar explained. “The material acts on the principle of ‘destroy and cleanse,’ ensuring a sterile environment while preventing infections.”

Promising results in animal trials

Animal testing has shown encouraging results, with the modified talc demonstrating sustained antibacterial activity. Professor Suleyman Koytepe from Inonu University’s Chemistry Department highlighted the material’s potential:

“The particle size has been carefully engineered to maintain antibacterial efficacy over an extended period. This advancement shortens the treatment process and enhances overall effectiveness. If the results continue to be positive, this method has a strong potential to be incorporated into medical literature.”

Minimal side effects, high success rates

Dr. Onural Ozhan, a pharmacology expert overseeing the animal testing phase, revealed that mortality rates in test subjects have been exceptionally low.

“Typically, mortality rates in such experimental models are quite high,” Ozhan stated. “However, with our newly developed product, we have observed significantly reduced animal losses. We are now proceeding with further analysis to determine its suitability for human applications.”

Additionally, Dr. Canbolat Gurses from the Department of Molecular Biology and Genetics at Inonu University confirmed that the antibacterial effect of the modified talc was noticeable within just five hours of application.

Step closer to clinical use

With the completion of initial animal trials, the researchers are now preparing for the rigorous testing required before human application. They have also initiated the international patent process to secure recognition for their innovation on a global scale.

If successful, this groundbreaking treatment could provide a long-term solution for millions suffering from pleural effusion and recurrent pneumothorax, offering a safer and more effective alternative to existing therapies.